See more : Goal Acquisitions Corp. (PUCKU) Income Statement Analysis – Financial Results
Complete financial analysis of Opthea Limited (OPT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Opthea Limited, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Azucar Minerals Ltd. (AXDDF) Income Statement Analysis – Financial Results
- Mobico Group Plc (NXPGF) Income Statement Analysis – Financial Results
- Uranium Energy Corp. (UEC) Income Statement Analysis – Financial Results
- Dirui Industrial Co.,Ltd. (300396.SZ) Income Statement Analysis – Financial Results
- Clear Channel Outdoor Holdings, Inc. (CCO) Income Statement Analysis – Financial Results
Opthea Limited (OPT)
About Opthea Limited
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema DME, as well as a first in class VEGF C/D inhibitors for treatment with VEGF A inhibitors for the treatment of wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 124.67K | 161.16K | 125.05K | 91.98K | 145.90K | 112.50K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.35K | 19.13K | 0.00 | 13.34K | 12.24K | 0.00 | 9.57K | 0.00 | 0.00 | 2.94B | 192.74K | 240.51K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 250.47K | 232.47K | 571.98K | 517.26K | 273.94K | 28.66K | 26.61K | 30.79K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 27.35K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 124.67K | -89.31K | -107.42K | -480.00K | -371.37K | -161.45K | -28.66K | -26.61K | -30.79K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.35K | 19.13K | 0.00 | 13.34K | 12.24K | 0.00 | 9.57K | 0.00 | -27.35K | 2.94B | 192.74K | 240.51K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | -55.42% | -85.91% | -521.85% | -254.54% | -143.51% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% | 0.00% | 100.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 176.33M | 181.56M | 108.46M | 34.71M | 17.48M | 31.35M | 24.89M | 4.84M | 3.58M | 4.28M | 3.40M | 3.14M | 3.68M | 7.02M | 3.65M | 3.62M | 3.27M | 2.67M | 1.20M | 533.75K | 349.78K | 106.50K | 144.69K | 553.00K | 186.15K | 358.33K | 600.34K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.67K | 0.00 | 0.00 |
| General & Administrative | 15.49M | 19.27M | 16.30M | 11.88M | 6.61M | 5.09M | 2.70M | 3.25M | 2.86M | 2.36M | 2.65M | 3.11M | 3.58M | 4.36M | 4.57M | 3.77M | 3.44M | 3.39M | 2.04M | 1.65M | 1.34M | 1.32M | 1.16M | 1.88M | 320.84K | 332.21K | 0.00 | 252.31K | 204.75K | 132.10K | 113.26K | 74.82K | 43.33K | 59.82K | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 22.63M | 8.52M | 6.54M | 43.14K | 108.90K | 2.29M | 629.16K | 613.02K | 359.30K | 477.17K | 538.63K | 467.15K | 713.42K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 76.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.49M | 41.90M | 24.83M | 18.42M | 6.65M | 5.20M | 4.99M | 5.03M | 4.47M | 2.36M | 2.65M | 3.11M | 3.58M | 4.36M | 4.57M | 3.77M | 3.44M | 3.39M | 2.04M | 1.65M | 1.34M | 1.32M | 1.16M | 1.88M | 320.84K | 332.21K | 0.00 | 252.31K | 204.75K | 132.10K | 113.26K | 74.82K | 43.33K | 59.82K | 0.00 | 0.00 |
| Other Expenses | 152.46K | 12.30M | 0.00 | 0.00 | 0.00 | 56.76K | 2.03K | 1.23K | 6.23K | 48.00K | 183.04K | 29.55K | 199.06K | 78.32K | 2.12K | 106.79K | 5.76K | 130.52K | 50.38K | 22.90M | 5.33M | 11.79K | 96.84K | 875.00K | 1.59M | 2.79M | 73.54K | 81.79K | 11.03K | 47.58K | 432.57K | 9.00K | 10.00K | 20.00K | 10.00K | 4.53K |
| Operating Expenses | 191.97M | 223.46M | 133.29M | 53.13M | 24.71M | 36.27M | 29.88M | 9.87M | 8.05M | 6.80M | 6.59M | 6.88M | 8.90M | 12.27M | 8.68M | 8.46M | 8.26M | 14.38M | 3.55M | 2.32M | 1.80M | 2.94M | 1.32M | 12.76K | 520.09K | 14.89M | 13.11K | 6.78K | 208.69K | 135.65K | 114.72K | 74.82K | 44.07K | 68.25K | 7.93K | -7.55K |
| Cost & Expenses | 191.97M | 223.61M | 133.40M | 53.27M | 25.23M | 36.54M | 29.91M | 9.90M | 8.08M | 6.80M | 6.59M | 6.88M | 8.90M | 12.27M | 8.68M | 8.46M | 8.26M | 14.38M | 3.55M | 2.32M | 1.80M | 2.94M | 1.32M | 12.76K | 547.44K | 14.89M | 13.11K | 6.78K | 208.69K | 135.65K | 114.72K | 74.82K | 44.07K | 68.25K | 7.93K | -7.55K |
| Interest Income | 3.39M | 4.80M | 324.70K | 498.70K | 696.18K | 755.78K | 735.70K | 384.35K | 325.57K | 324.56K | 258.85K | 530.99K | 998.39K | 1.48M | 1.39M | 1.86M | 3.12M | 1.73M | 815.55K | 1.14M | 617.15K | 569.19K | 579.33K | 1.59M | 326.53K | 106.45K | 72.52K | 158.75K | 82.69K | 54.69K | 36.54K | 7.35K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 30.26M | 20.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 576.11K | 0.00 | 391.82K | 0.00 | 0.00 | 71.87K | 179.45K | 0.00 | 0.00 | 1.13K | 8.16K | 0.00 | 0.00 | 1.98M | 1.40M | 787.50 | 1.42K | 1.46K | 668.00 | 2.24K | 5.37K | 3.97K | 7.55K | |
| Depreciation & Amortization | 103.03K | 150.49K | 108.08K | 143.00K | 144.02K | 33.09K | 28.66K | 26.61K | 30.79K | 29.58K | 35.98K | 24.95K | 29.25K | 30.02K | 24.30K | 27.49K | 29.98K | 25.42K | 13.69K | 23.86K | 26.59K | 0.00 | 16.33K | 12.76K | 13.10K | 14.89M | 13.11K | 6.78K | 3.94K | 3.55K | 1.46K | -273.21K | 747.00 | 766.90 | 7.93K | -7.55K |
| EBITDA | -200.02M | -223.30M | -133.16M | -52.85M | -24.92M | -36.64M | -29.74M | -9.80M | -7.72M | -8.08M | -6.81M | -6.54M | -7.45M | -11.05M | -9.63M | -9.24M | -8.22M | -37.88M | -4.41M | 21.89M | -2.54M | -2.94M | -3.22M | -807.30K | -534.34K | 2.94B | 192.74K | 240.51K | -967.05K | -522.00K | -78.92K | -348.03K | -72.46K | -163.35K | -627.42K | -511.89K |
| EBITDA Ratio | -160,443.72% | -138,554.61% | -106,489.56% | -57,660.19% | -16,914.89% | -32,565.84% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -87,982.98% | -198,006.39% | 0.00% | 132,162.03% | -14,580.37% | 0.00% | -33,605.88% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -191.84M | -223.45M | -133.27M | -53.18M | -24.70M | -36.67M | -29.91M | -9.90M | -8.08M | -7.00M | -6.29M | -7.25M | -8.95M | -11.23M | -10.17M | -7.57M | -12.66M | -37.90M | -3.92M | 17.61M | -1.81M | -2.97M | -3.25M | -833.02K | -547.44K | -741.67K | -1.23M | -1.06M | -970.99K | -525.55K | -80.38K | -74.82K | -73.21K | -164.12K | -635.35K | -504.34K |
| Operating Income Ratio | -153,885.37% | -138,647.99% | -106,575.99% | -57,815.66% | -16,929.71% | -32,595.25% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -88,191.87% | -198,139.25% | 0.00% | 131,983.17% | -14,797.71% | 0.00% | -33,943.71% | 0.00% | 0.00% | -0.03% | -638.09% | -439.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -37.81M | -70.67M | -3.41M | -14.23M | 310.76K | 1.03M | 2.98M | 535.06K | -16.02K | 2.24M | 1.16M | 958.26K | 1.72M | 855.19K | 1.17M | -1.70M | 7.18M | 24.55M | -661.28K | -1.01M | 5.87M | 495.02K | -1.92M | -8.17K | 1.28M | 2.32M | -771.54K | -1.04M | 81.90K | 53.27K | 35.07K | -266.53K | 12.70K | 25.31K | 142.78K | 93.62K |
| Income Before Tax | -229.65M | -220.69M | -136.68M | -67.41M | -24.39M | -35.55M | -28.92M | -9.36M | -8.10M | -6.23M | -6.45M | -5.99M | -7.48M | -11.80M | -5.81M | -7.97M | -1.07M | 10.19M | -4.58M | 16.60M | 4.06M | -2.45M | -3.23M | -828.22K | 730.42K | 1.58M | -1.23M | -1.06M | -889.09K | -472.28K | -45.30K | -341.35K | -60.51K | -138.81K | -492.58K | -410.72K |
| Income Before Tax Ratio | -184,215.67% | -136,936.62% | -109,300.18% | -73,285.73% | -16,716.71% | -31,598.21% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -7,445.89% | 53,289.60% | 0.00% | 124,394.23% | 33,158.07% | 0.00% | -33,788.24% | 0.00% | 0.00% | 0.05% | -638.09% | -439.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -9.41M | -8.81M | -8.69M | -6.62M | 8.27M | 14.64M | -12.02M | -3.17M | -1.57M | -2.09M | -2.69M | -1.42M | -2.46M | -831.43K | 93.06K | 37.02K | 1.12M | 4.85M | 252.37K | 2.79K | -5.87M | -83.76K | 85.58 | -39.80K | -1.28M | 2.37M | -1.98M | -1.40M | -1.13M | -665.00K | -62.00K | -511.00K | -81.00K | -181.00K | -621.00K | -544.00K |
| Net Income | -220.24M | -211.88M | -127.99M | -60.79M | -16.12M | -20.91M | -16.90M | -6.19M | -6.51M | -4.07M | -3.76M | -4.34M | -4.95M | -10.97M | -5.91M | -8.00M | -1.10M | 9.50M | -4.80M | 16.60M | 4.06M | -2.36M | -3.23M | -801.17K | 730.42K | 1.58B | -1.23M | -1.05M | -857.59K | -472.28K | -45.30K | -341.35K | -60.51K | -138.81K | -492.58K | -410.72K |
| Net Income Ratio | -176,665.73% | -131,469.80% | -102,353.69% | -66,087.58% | -11,047.04% | -18,587.22% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -7,652.13% | 49,675.59% | 0.00% | 124,404.80% | 33,158.07% | 0.00% | -33,788.24% | 0.00% | 0.00% | 53.84% | -638.09% | -438.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.77 | -0.45 | -0.34 | -0.18 | -0.06 | -0.09 | -0.07 | -0.03 | -0.04 | -0.04 | -0.07 | -0.09 | -0.10 | -0.23 | -0.13 | -0.18 | -0.03 | 0.23 | -0.12 | 0.40 | 0.10 | -0.06 | -0.08 | -0.02 | 0.02 | 48.81 | -0.03 | -0.03 | -0.03 | -0.02 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -2.77 | -0.45 | -0.34 | -0.18 | -0.06 | -0.09 | -0.07 | -0.03 | -0.04 | -0.04 | -0.07 | -0.09 | -0.10 | -0.23 | -0.13 | -0.18 | -0.03 | 0.23 | -0.12 | 0.40 | 0.10 | -0.06 | -0.08 | -0.02 | 0.02 | 48.81 | -0.03 | -0.03 | -0.03 | -0.02 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 79.78M | 469.56M | 372.94M | 339.92M | 260.50M | 232.80M | 232.17M | 185.69M | 172.99M | 115.73M | 52.78M | 48.57M | 47.61M | 47.32M | 46.29M | 45.65M | 41.05M | 41.32M | 41.05M | 41.05M | 41.10M | 42.24M | 42.20M | 41.83M | 33.62M | 32.42M | 35.49M | 36.12M | 27.17M | 26.07M | 25.37M | 24.51M | 22.31M | 232.80M | 232.80M | 232.80M |
| Weighted Avg Shares Out (Dil) | 79.78M | 469.56M | 372.94M | 339.92M | 260.80M | 232.80M | 232.17M | 185.69M | 172.99M | 115.73M | 52.78M | 49.71M | 47.61M | 47.32M | 46.29M | 45.65M | 41.05M | 41.32M | 41.05M | 41.05M | 41.10M | 42.24M | 42.20M | 41.83M | 33.62M | 32.42M | 35.49M | 36.12M | 27.17M | 26.07M | 25.37M | 24.51M | 22.31M | 232.80M | 232.80M | 232.80M |
Opthea Receives A$8.8 million R&D Tax Incentive
MELBOURNE, Australia, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that it has received an A$8.8 million (US$5.9 million) research...
Opthea to Present at the FLORetina 2023 Congress
MELBOURNE, Australia, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced an oral presentation featuring sozinibercept (OPT-302) which will be presented...
Opthea to Present at the Jefferies 2023 London Healthcare Conference
MELBOURNE, Australia, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company's Founder and Chief Innovation...
Opthea to Present at Eyecelerator Forum at the 2023 American Academy of Ophthalmology (AAO) Conference
MELBOURNE, Australia, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company's Founder & Chief Innovation...
Opthea Appoints U.S.-Based Leadership with Fred Guerard as CEO and Peter Lang as CFO
Dr. Megan Baldwin transitions to Founder, Chief Innovation Officer and remains on the Board of Directors
Opthea to Participate at the 2023 Euretina Congress
MELBOURNE, Australia, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that on October 4th, Dr. Megan Baldwin, the Company's Chief...
Opthea to Present at the H.C. Wainwright 25th Annual Global Investment Conference
MELBOURNE, Australia, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Mr. Tim Morris, the Company's Chief Financial Officer will...
Opthea Successfully Completes Institutional Offer and Increases Capital Raising to A$90.0m (US$57.6 million¹)
MELBOURNE, Australia, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (Opthea or the Company) (ASX:OPT; NASDAQ:OPT) is pleased to announce the successful completion of the institutional component of the capital raising announced on Thursday, 24 August 2023.
Opthea Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302
MELBOURNE, Australia, July 26, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that the American Medical Association's United States Adopted Names (USAN)...
Opthea to Present at the 2023 Ophthalmology Innovation Summit
MELBOURNE, Australia, July 24, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company's Chief Executive Officer will...
Source: https://incomestatements.info
Category: Stock Reports